GAtherton

Aspergillosis in Pets: A Practical Guide for Owners

Last reviewed: March 2026

Key Points

  • Aspergillosis is an environmental fungal infection, not contagious between pets or people.
  • Dogs are most commonly affected, particularly in the nose and sinuses.
  • Risk increases with exposure to disturbed soil, compost, and decaying plant material.
  • Different animals are affected in different ways depending on behaviour and anatomy.
  • Early recognition and veterinary treatment usually lead to good outcomes.

Table of Contents

What is aspergillosis?

Aspergillosis is caused by Aspergillus, a group of moulds commonly found in soil, compost, and decaying vegetation. Pets are exposed to these spores regularly in everyday environments.

In dogs, the infection most often affects the nasal passages and sinuses. In other animals, particularly birds, it more commonly affects the lungs.

Important: This is not a contagious disease. It is acquired from the environment.

Which pets are more susceptible?

Dogs

  • Most commonly affected species
  • Higher risk in long-nosed breeds (e.g. German Shepherds, Collies, Greyhounds)
  • Risk increased by sniffing, digging, and outdoor exploration

Cats

  • Less commonly affected
  • Can develop nasal or sinus infection, occasionally more invasive

Birds

  • Most sensitive species
  • Infection usually affects the lungs and air sacs
  • Risk increased in dusty or poorly ventilated environments

Other animals

  • Farm animals (e.g. horses) can be affected, but this is uncommon
  • Small pets (rabbits, rodents) are rarely affected

Do risks differ between animals?

Yes. The same environment can pose different risks depending on how an animal interacts with it.

  • Dogs: close to the ground → inhale spores while sniffing or digging
  • Cats: roaming behaviour → exposure in gardens, sheds, and debris
  • Birds: airborne exposure → sensitive lungs affected in enclosed or dusty spaces

Key insight: The common factor is exposure to fungal spores, but the route of exposure differs between species.

Warning signs to look out for

Dogs (most common presentation)

  • Persistent nasal discharge (often one-sided)
  • Sneezing
  • Nosebleeds
  • Pain around the nose

More advanced signs

  • Swelling around the nose or eyes
  • Loss of pigment or ulceration on the nose
  • Lethargy or reduced appetite

Birds

  • Breathing difficulty
  • Lethargy
  • Reduced appetite

Key message: Persistent symptoms—especially nasal discharge or breathing problems—should always be checked by a vet.

Environmental risks: what to avoid

Aspergillus grows in decaying organic material. Risk increases when this material is disturbed and spores become airborne.

Higher-risk environments

  • Disturbed soil (construction or garden clearance)
  • Rotting leaves, wood, or plant debris
  • Compost heaps and garden waste
  • Bark chippings or mulch
  • Stored hay, straw, or grain
  • Dusty sheds, barns, or enclosed spaces

Situations that increase exposure

  • Digging or burrowing
  • Prolonged sniffing in debris-rich areas
  • Dry, windy conditions
  • Poor ventilation (especially for birds)

Common factors across all pets

  • Decaying organic material
  • Disturbance of soil or vegetation
  • Dust and airborne particles
  • Enclosed or poorly ventilated environments

Simple precautions

  • Keep dogs on a lead near disturbed areas
  • Avoid allowing pets to dig in compost or debris
  • Keep bird enclosures clean and well ventilated
  • Allow disturbed sites to settle before use
  • Rinse paws and muzzle after muddy walks

Balanced view: These environments are common and most pets are exposed without becoming ill. The aim is to reduce exposure during higher-risk periods.

Treatment and management

Aspergillosis in dogs is usually treatable and often curable.

Typical treatment

  • Antifungal medication applied directly into the nasal passages under anaesthetic
  • Removal of fungal material (debridement)

Other approaches

  • Oral antifungal medication in selected cases
  • Supportive care (pain relief, monitoring)

Follow-up is important to ensure the infection has fully cleared.

Risk to people and other pets

  • Not contagious between animals or humans
  • Healthy people are at very low risk
  • Higher-risk individuals are those with lung disease or weakened immune systems

When to seek veterinary advice

  • Nasal discharge lasting more than a few days
  • Blood from the nose
  • Persistent sneezing or discomfort
  • Breathing problems (especially in birds)
  • Swelling around the face

Early diagnosis improves outcomes significantly.

Common questions

Can pets catch aspergillosis from people?

No. It is acquired from the environment.

Is a damp home a cause?

Damp environments can contain spores, but most cases—especially in dogs—are linked to outdoor exposure.

Is this common?

It is uncommon overall, but a recognised cause of nasal disease in dogs.

Summary

Aspergillosis is an environmental fungal infection that affects different animals in different ways. Dogs are most commonly affected through sniffing contaminated material, while birds are more sensitive to airborne spores in enclosed spaces. Although exposure is common, illness is uncommon, and simple precautions combined with early veterinary care usually lead to good outcomes.

Author: Aspergillosis Patient Support & Education Team

Review: This information is for general guidance only and does not replace veterinary advice. If you are concerned about your pet, please consult your veterinary surgeon.

by GAtherton

Why Join an Online Support Group if You Have Aspergillosis?

You are not alone with aspergillosis

Join a friendly online support meeting — no pressure, just listen if you prefer.

Many patients find that even attending once helps them feel more reassured, informed, and supported.


View meeting times and book your place

Why Join an Online Support Group if You Have Aspergillosis?

Living with aspergillosis can feel isolating. Many people go for years without meeting another person with the same condition. Family and friends may be supportive, but they may not fully understand what it is like to live with breathlessness, fatigue, treatment side effects, uncertainty, or repeated hospital visits.

That is one reason online support groups can be so valuable. They bring people together who understand, often immediately, many of the challenges that aspergillosis can bring.

Key points

  • Online support groups reduce isolation and help patients feel understood
  • They offer shared experience alongside emotional support
  • They improve confidence and understanding of the condition
  • They help patients feel better prepared for appointments
  • They are flexible — you can simply listen if you prefer

What changes when people join a support group?

Before joining

  • Feeling alone with the condition
  • Uncertainty about symptoms
  • Limited practical advice
  • Low confidence at appointments
  • Worry about the future

After joining

  • Connection with others who understand
  • Better understanding of the condition
  • Practical day-to-day coping ideas
  • More confidence asking questions
  • Feeling more supported and reassured

Why aspergillosis can feel so isolating

Aspergillosis is a relatively rare condition, and many patients never meet someone else with the same diagnosis. Online support groups help bridge that gap by creating a shared space for understanding and connection.

1. You realise you are not alone

Hearing others describe similar symptoms and challenges can be immediately reassuring and reduce feelings of isolation.

2. Shared experience can be deeply reassuring

Support groups provide practical, real-world insight into managing fatigue, pacing, work, and daily life.

3. You may understand your condition better

Listening to others and accessing shared resources helps build confidence and understanding.

4. It can help you feel more confident at appointments

Patients often feel better prepared and more able to ask the right questions.

5. Emotional support matters too

These groups provide encouragement, understanding, and a sense of belonging.

What happens in a typical online support session?

  • Friendly welcome — no pressure to speak
  • Open discussion — share or listen
  • Optional topics — such as fatigue or treatment experiences
  • Flexible participation — camera and microphone optional
  • Safe, moderated space

Many people attend their first session just to listen — and that is completely fine.

What patients often say

“I wish I had joined sooner. Just hearing others talk made a huge difference.”

“I didn’t speak in my first meeting, but it really helped just listening.”

“It helped me understand my condition and feel more confident.”

Thinking of joining?

You can attend once, listen, and decide if it feels helpful. There is no obligation to continue.

View meeting times and book here:

https://aspergillosis.org/support-meetings/

Meetings are held online using Microsoft Teams. You will receive a joining link after booking.

Bottom line

Online support groups offer connection, reassurance, and understanding. They cannot replace medical care, but they can make living with aspergillosis feel more manageable and less lonely.

Please note: These groups are for support and shared experience. They do not replace advice from your own doctor or specialist team.

by GAtherton

Donating Your Body for Medical Research in the UK

Including research that may help conditions such as aspergillosis

This is an uncommon request, but it can be very helpful to researchers. There is no compulsion at all to consider body donation. It is entirely a personal choice. Many people will decide that it is not for them, and that is completely understandable. For those who do wish to explore it, however, body donation can make an important contribution to medical education, training, and research.

What does body donation mean?

In the UK, donating your body means leaving it after death to a medical school or other appropriately licensed institution for anatomical examination, education, training, or research.

You cannot usually donate your body specifically to “aspergillosis research” alone. However, donation may still support work that is highly relevant to people affected by aspergillosis, including:

  • lung disease
  • infection
  • immune responses
  • medical training in complex respiratory illness

The most important point: consent must be given in advance

Under UK law, body donation must be arranged before death. This means:

  • you must give written consent
  • the consent must usually be witnessed
  • your family cannot normally make this decision for you after you die

How to arrange body donation

  1. Choose a medical school
    You need to contact a medical school directly. Most only accept donations from their local area.
  2. Request an information pack
    The school will explain its process, send consent forms, and set out any restrictions.
  3. Complete the consent forms
    Keep copies with your important papers and let your family know your wishes.
  4. Tell your next of kin or executor
    They will usually need to contact the medical school promptly after death.

Important to understand

  • Not every donation can be accepted. Even if you have registered, a medical school may not be able to accept the body in every circumstance.
  • A backup funeral plan is important.
  • Body donation is separate from organ donation. They are different systems and require separate arrangements.

Can I ask for donation to help lung or aspergillosis-related research?

You can certainly explain that your interest is in supporting research and education relevant to lung disease, infection, or aspergillosis. However, you cannot usually guarantee exactly how a donated body will be used. Even so, donation may still support education and research that benefits future patients with complex respiratory and fungal conditions.

Where to start: Human Tissue Authority

The best first step is the Human Tissue Authority (HTA), which provides UK guidance and a way to identify the correct medical school for your postcode.

Examples of medical school body donation pages

Please note: contact details and catchment arrangements can change, so it is wise to confirm current information directly on each medical school’s website.

Final thought

Donating your body for medical education or research is an unusual and deeply personal decision. There is absolutely no obligation to consider it. But for those who do, it can be a generous and lasting way to support future learning, better care, and research that may help people living with serious conditions, including aspergillosis.

Last reviewed: March 2026

by GAtherton

How Inflammation in One Part of the Body Can Affect the Rest of the Body

Last reviewed: 24 March 2026
Audience: Patients, families, and non-specialist clinicians
Author: Aspergillosis.org editorial team

Many people think of inflammation as something that stays in one place: a painful joint, an inflamed lung, an irritated sinus, or a bowel flare. In reality, inflammation is often a whole-body process. Signals released at one site can travel through the blood, nervous system, and immune system, influencing other organs and changing how the body feels and functions overall.

This helps explain why a local health problem can sometimes lead to symptoms that seem much broader, such as fatigue, poor concentration, low mood, loss of appetite, aches, disturbed sleep, or worsening of other long-term conditions.

Key points

  • Inflammation is not always confined to one organ or body part.
  • Inflamed tissues release chemical messengers that can circulate throughout the body.
  • The brain, heart, kidneys, liver, gut, lungs, and immune system all communicate with one another.
  • This “cross-talk” can be helpful in short-term illness, but harmful when inflammation becomes prolonged.
  • Ongoing inflammation is linked with fatigue, brain fog, low mood, cardiovascular strain, and worsening of other chronic diseases.

Table of contents

What is inflammation?

Inflammation is part of the body’s defence system. It is one of the ways the immune system responds to infection, injury, irritation, allergens, or tissue damage. In the short term, inflammation is often helpful. It can help the body fight infection, clear damaged tissue, and begin repair.

But inflammation can also become too strong, too prolonged, or poorly controlled. When that happens, the effects may no longer stay limited to the original problem area.

Why inflammation does not always stay local

When tissue becomes inflamed, immune cells release small signalling proteins called cytokines and other inflammatory mediators. These act like chemical messages. Some stay nearby, but many enter the bloodstream and influence distant organs.

This is why inflammation in one part of the body can sometimes cause:

  • tiredness or exhaustion
  • feeling unwell or “washed out”
  • poor concentration or “brain fog”
  • worsening appetite
  • sleep disruption
  • higher strain on the heart or kidneys
  • worsening of other inflammatory conditions

Researchers increasingly describe this as systemic inflammation or organ cross-talk. In other words, organs do not operate in isolation. They are part of an interconnected network.

How the body communicates during inflammation

1. Chemical messengers in the blood

Inflamed tissues can release cytokines such as interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and tumour necrosis factor alpha (TNF-α). These may affect blood vessels, metabolism, the brain, the heart, and other immune cells.

These signals are useful during short-term illness, but if they remain elevated they may contribute to chronic symptoms and long-term health effects.

2. Organ-to-organ immune cross-talk

Modern immunology shows that the gut, liver, lungs, brain, heart, kidneys, and bone marrow can influence one another through immune signalling. A problem in one organ may therefore alter immune behaviour somewhere else.

This can be protective, but it can also become part of a vicious circle, especially in chronic disease.

3. Nerve signalling between the body and brain

Inflammation is not communicated only by blood. The nervous system also plays a role. Signals from inflamed tissues can travel through nerves, including the vagus nerve, to the brain. The brain then responds by adjusting immune activity and body-wide stress responses.

This helps explain why inflammation can affect fatigue, mood, motivation, sleep, and mental clarity.

4. Stress, hormones, and metabolism

Inflammation also interacts with the body’s hormonal and metabolic systems. This can influence energy use, blood sugar regulation, muscle strength, and appetite. Over time, chronic inflammation may put extra strain on the cardiovascular and kidney systems.

Common whole-body effects of inflammation

Fatigue

One of the most common effects of inflammation is fatigue. This is not simply feeling sleepy. It can be a profound lack of physical and mental energy. Many chronic inflammatory illnesses are associated with this kind of exhaustion.

Brain fog and mood changes

Inflammatory signals can affect the brain, contributing to reduced concentration, slowed thinking, low motivation, anxiety, or low mood. This does not mean symptoms are “all in the mind”. It means that immune activity can influence brain function.

Heart and blood vessel effects

Inflammation can make blood vessels less healthy over time and may contribute to a higher cardiovascular risk. This is one reason why long-standing inflammatory diseases are often linked to heart and circulatory problems.

Kidney effects

The kidneys are sensitive to inflammatory stress. In some conditions, long-term systemic inflammation can contribute to kidney damage or worsen existing kidney disease. Kidney disease itself can also increase inflammation, creating a two-way relationship.

Muscle weakness and reduced stamina

Ongoing inflammation can alter how muscles use energy and recover after activity. This may contribute to weakness, reduced exercise tolerance, and slower recovery after exertion.

Why this matters in lung disease and aspergillosis

For people with chronic lung conditions, including some forms of aspergillosis, inflammation in the airways or lungs may have effects beyond breathing alone. The lungs are not separate from the rest of the body.

Inflammation in the lungs may contribute to:

  • general fatigue
  • poor stamina
  • sleep disruption
  • brain fog
  • loss of appetite
  • worsening of other conditions

This can be especially relevant for people living with long-term inflammatory lung disease, repeated infections, allergic inflammation, or complex treatment burdens.

It is also one reason why patients sometimes feel that their symptoms are “bigger” than what would be expected from the lungs alone. Often, that experience is real and biologically plausible.

Acute inflammation versus chronic inflammation

Acute inflammation

This is the short-term response seen with infection, injury, or a sudden flare. It may cause fever, pain, swelling, and marked tiredness. Usually, it settles when the trigger is controlled.

Chronic inflammation

This is lower-grade or persistent inflammation that continues over time. It may be driven by chronic infection, immune dysregulation, ongoing tissue damage, obesity, autoimmune disease, long-term lung disease, or other medical problems. Chronic inflammation is often less dramatic but may have broader long-term effects.

What can help?

The right approach depends on the underlying cause. Broadly, management focuses on:

  • identifying and treating the cause of inflammation where possible
  • controlling infections or allergic triggers
  • optimising treatment of the underlying disease
  • supporting sleep, nutrition, and pacing of activity
  • monitoring the effects on other organs when relevant

There is rarely a single quick fix for chronic inflammation. Good management usually means looking at the whole person, not just the inflamed organ.

When to seek medical advice

Please seek medical advice if inflammation-related symptoms are worsening or if you develop:

  • new or severe breathlessness
  • chest pain
  • confusion or marked drowsiness
  • new swelling, reduced urine output, or signs of dehydration
  • persistent fevers
  • rapid decline in energy, mobility, or daily functioning

If symptoms are sudden, severe, or alarming, seek urgent medical help.

Common questions

Does inflammation always damage the whole body?

No. Short-term, controlled inflammation is a normal and useful response. Problems are more likely when inflammation is severe, repeated, or persistent.

Can one inflamed organ affect another?

Yes. There is now strong evidence that organs influence one another through immune, vascular, metabolic, and nerve-based pathways.

Can inflammation cause fatigue even if blood tests are not dramatically abnormal?

Yes. Symptoms and blood markers do not always match perfectly. Some people experience substantial fatigue and other systemic symptoms even when routine blood tests are only mildly abnormal or intermittently raised.

Is this relevant to chronic lung disease?

Yes. Lung inflammation can have effects that go beyond breathing, including fatigue, reduced stamina, and wider body effects.

References

  1. Dou J, et al. The Interplay of Cross-Organ Immune Regulation in Inflammation and Cancer. MedComm. 2025.
  2. Jin H, Li M, et al. A body–brain circuit that regulates body inflammatory responses. Nature. 2024.
  3. Katkenov N, et al. Systematic Review on the Role of IL-6 and IL-1β in Cardiovascular Diseases. Journal of Cardiovascular Development and Disease. 2024.
  4. Nowak KL, et al. Targeting Inflammation in CKD. Current Opinion in Nephrology and Hypertension. 2025.
  5. Paganin W, et al. Inflammatory biomarkers in depression: a scoping review. 2024.
  6. Mehta NN, et al. IL-6 and Cardiovascular Risk: A Narrative Review. 2024.
  7. Che H, et al. Organ cross-talk: molecular mechanisms, biological functions and therapeutic opportunities. 2026.

Disclaimer: This article is for general information and education. It is not a substitute for personalised medical advice. If you are worried about worsening symptoms, new symptoms, or the effect of inflammation on your health, speak to your clinical team.

by GAtherton

Aspergillosis Research Update (Week of 16–23 March 2026)

This week’s aspergillosis literature includes important new work on chronic pulmonary aspergillosis (CPA), aspergilloma microbiology, azole resistance evolution, biomarkers, allergic bronchopulmonary aspergillosis (ABPA), and surveillance. As usual, the most clinically useful papers for long-term aspergillosis care are prioritised.

Key points summary

  • New evidence suggests that azole persistence and stress tolerance may develop before overt antifungal resistance becomes detectable.
  • An aspergilloma appears to be more than a simple fungal ball: it may function as a complex microbial ecosystem involving bacterial adaptation and persistence.
  • A new surveillance paper argues for moving beyond Aspergillus fumigatus strain surveillance toward clinical disease surveillance.
  • ABPA review literature continues to reflect growing interest in biologic therapies as steroid-sparing treatment.
  • A case report reminds clinicians that lung cancer can mimic recurrent aspergillosis, with potential for diagnostic delay.
  • Biomarker studies in invasive pulmonary aspergillosis (IPA) are continuing, although most are not yet ready for routine clinical use.

Contents

  1. Chronic and structural disease
  2. Antifungal resistance and fungal evolution
  3. Diagnosis and biomarkers
  4. ABPA and allergic disease
  5. Surveillance, epidemiology and environment
  6. Case reports and diagnostic challenges
  7. Other relevant papers

1. Chronic and structural disease

Pseudomonas aeruginosa adaptation and persistence in the aspergilloma microbiome revealed by integrated multi-omics

Ribeiro MM, Liu C, Xu JF, Liang S, Goldman GH
G3 (Bethesda), 17 March 2026
PMID: 41843749

This is one of the most interesting papers this week for those focused on CPA and aspergilloma. The authors examine the microbial ecology of aspergilloma and show that Pseudomonas aeruginosa can adapt and persist within this environment. That matters because aspergilloma has often been thought of mainly as a fungal structure, whereas this paper supports the idea that it may be a more complex polymicrobial niche.

The study strengthens the view that chronic pulmonary aspergillosis may involve not only fungal persistence, but also bacterial-fungal interactions, biofilm-like behaviour, and long-term microbial adaptation. This may help explain why some patients remain symptomatic despite antifungal therapy, and why structural lung disease can be so difficult to stabilise.

Why it matters:

  • Highly relevant to aspergilloma and CPA.
  • Supports growing interest in the lung microbiome and mixed microbial communities.
  • May eventually influence how we think about treatment failure, chronic symptoms, and combined antimicrobial strategies.

2. Antifungal resistance and fungal evolution

Evidence that increased azole persistence and stress resistance precede the in vivo evolution of azole resistance in Aspergillus fumigatus

Delbaje E, Pontes L, Savoldi M, Sedik S, Dichtl K, Hoenigl M, Lass-Flörl C, Silva Pereira C, Schreiber AZ, Rokas A, Lu L, Barbosa JCJ, Fill T, Dos Reis TF, Goldman GH
Microbiology Spectrum, 16 March 2026
PMID: 41837673

This is an important resistance paper. The authors provide evidence that azole persistence and stress resistance may emerge before formal azole resistance becomes established in vivo. In other words, the fungus may first become better at surviving azole exposure before developing the classical resistance patterns that laboratories can detect more easily.

That finding is highly relevant to patients with chronic aspergillosis receiving prolonged azole therapy. It suggests that the road to treatment failure may begin earlier than clinicians currently realise, and that traditional susceptibility testing may capture resistance only after important adaptive changes are already underway.

Why it matters:

  • Very important for CPA management and long-term triazole treatment.
  • Suggests that “susceptible” isolates may still show clinically relevant survival advantages.
  • May help explain some cases of gradual loss of treatment response before overt resistance is identified.

Accelerated mutator phenotype in a clinical Aspergillus fumigatus isolate contributes to adaptive evolution

Song Y, Hokken MWJ, Zoll J, Venselaar H, Verweij PE, Melchers WJG, Rhodes J
Emerging Microbes & Infections, 16 March 2026
PMID: 41838943 |
PMCID: PMC12997362

This paper complements the study above. It describes a clinical Aspergillus fumigatus isolate with an accelerated mutator phenotype, meaning it acquires mutations more readily and can therefore adapt more quickly under selective pressure.

For chronic disease, especially where patients receive long courses of azole therapy, this is a concerning but important concept. Some fungal strains may be inherently more capable of adapting during treatment, which could contribute to the emergence of resistance, persistence, or other survival advantages.

Why it matters:

  • Relevant to CPA, azole resistance, and treatment monitoring.
  • Supports the idea that fungal evolution during chronic infection may be dynamic and patient-specific.
  • May eventually help explain why some patients develop resistance more rapidly than others.

3. Diagnosis and biomarkers

Synergistic effects of S100 calcium-binding protein A12 combined with Pentraxin 3 in invasive pulmonary aspergillosis and their clinical application prospects

Zhou X, Hu X, Liu H
Frontiers in Cellular and Infection Microbiology, 20 March 2026
PMCID: PMC12999553

This paper focuses on invasive pulmonary aspergillosis rather than chronic disease. It explores whether combining host biomarkers such as S100A12 and Pentraxin 3 could improve diagnosis and perhaps risk stratification.

As with many biomarker studies, the concept is promising, but the clinical pathway remains uncertain. Biomarkers that reflect the host inflammatory response may ultimately complement fungal biomarkers and imaging, particularly in intensive care or immunocompromised settings.

Why it matters:

  • More relevant to IPA than CPA or ABPA.
  • Illustrates continued interest in host-response biomarkers.
  • Potentially useful in the future, but not immediately practice-changing for routine aspergillosis care.

Diagnostic and prognostic value of serum miR-155 in chronic obstructive pulmonary disease

Wu Y, Zhang K, Zhong R, Wang W, Luo Z, Ma Z, Liang R, Wu X, Zou X
Scientific Reports, 20 March 2026
PMID: 41857172

This is not primarily an aspergillosis paper, but it includes findings relevant to invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease (COPD). The authors report that serum miR-155 levels were lower in IPA than non-IPA patients within their study population.

That is potentially interesting because COPD is a major risk factor for IPA, and there is growing need for better tools to identify invasive fungal disease in such patients. However, this remains exploratory and should be viewed as an early biomarker signal rather than something ready for clinical use.

Why it matters:

  • Relevant mainly for COPD-associated IPA risk.
  • Adds to the biomarker literature, but is not yet directly applicable in routine practice.
  • Limited immediate relevance for CPA and ABPA.

4. ABPA and allergic disease

Allergic bronchopulmonary aspergillosis in internal medicine

Chedal-Anglay C, Martin de Frémont G, Dupin C
Revue de Médecine Interne, 18 March 2026
PMID: 41856838

This review provides an overview of allergic bronchopulmonary aspergillosis, its diagnosis, and treatment. It reiterates that ABPA is a complex and often under-recognised inflammatory lung disease in which treatment may target inflammation, fungal burden, or both.

Importantly, the review reflects current momentum behind biotherapies (biologics) as a growing part of management. This is particularly relevant for patients in whom long-term corticosteroid exposure is problematic, ineffective, or poorly tolerated.

Why it matters:

  • A useful review paper for ABPA education and clinical context.
  • Supports the continuing move toward steroid-sparing treatment approaches.
  • Relevant to current discussions about personalised management pathways in ABPA.

5. Surveillance, epidemiology and environment

From Aspergillus fumigatus pathogen surveillance to Aspergillus disease surveillance

van Grootveld R, van der Beek MT, Buil JB, Schoffelen AF, de Greeff SC, Bosch T, de Boer MGJ, Kuijper EJ, Verweij PE
Journal of Hospital Infection, 18 March 2026
PMID: 41862136

This is an important conceptual paper. Rather than focusing solely on surveillance of Aspergillus fumigatus as an organism, the authors argue for broader Aspergillus disease surveillance. That is a significant distinction: public health and healthcare systems may gain more by tracking actual disease burden, clinical phenotypes, antifungal resistance patterns, and outcomes than by looking only at isolates.

For services interested in national strategy, referral equity, or long-term burden of disease, this paper points toward a more mature surveillance model. It has particular relevance to discussions about CPA burden, referral pathways, registry development, and national service planning.

Why it matters:

  • Important for policy, national strategy, and service development.
  • Supports the case for stronger data systems around aspergillosis burden and outcomes.
  • Potentially relevant to UK service planning and inequity mapping work.

A deep dive into the diversity of the Aspergillus community in the lakes of northern Iran

Kor M, Hedayati M, Abastabar M, Haghani I, Nabili M, Saravani A, Javidnia J, Brandão J, Moazeni M
Frontiers in Public Health, 20 March 2026
PMCID: PMC12999566

This environmental study analyses the diversity of Aspergillus species in lake environments and identifies potentially pathogenic species in water and sediment samples. It is not a clinical paper, but it adds to the wider evidence base showing that environmental reservoirs of Aspergillus are varied and widespread.

Such work contributes to broader understanding of exposure pathways and may be relevant to discussions around damp environments, environmental fungal burden, and risk in vulnerable individuals.

Why it matters:

  • Mainly relevant as background epidemiology and environmental context.
  • Useful for the bigger public-health picture of Aspergillus exposure.
  • Limited immediate clinical impact for patient management.

6. Case reports and diagnostic challenges

Case Report: Lung squamous cell carcinoma mimicking recurrent aspergillosis in systemic lupus erythematosus

Yu J, Tang Y, Tian S, Zhu W, Dai Q
Frontiers in Medicine, 22 March 2026
PMCID: PMC13002587

This case report is particularly valuable because it highlights a major diagnostic pitfall: lung squamous cell carcinoma presenting as recurrent aspergillosis. In patients with complex lung disease or immunological disease, it can be tempting to interpret recurring pulmonary abnormalities through the lens of known infection, inflammation, or prior fungal disease. This paper is a reminder that alternative diagnoses, including malignancy, must remain in view.

For patients with chronic pulmonary abnormalities, repeated “flare” narratives can sometimes delay the recognition of another process. This has strong relevance for clinical vigilance in CPA and related diagnostic pathways.

Why it matters:

  • Important reminder that not everything that looks like recurrent aspergillosis is aspergillosis.
  • Relevant to diagnostic delay, differential diagnosis, and the overlap between fungal disease and cancer.
  • Useful for clinician education and patient-facing discussion about why diagnosis can sometimes take time.

7. Other relevant papers

Genetic background and immune response in paracoccidioidomycosis: A systematic review and meta-analysis of single nucleotide variants

Coelho SDS, Fava WS, Burger E, Pereira-Latini AC, Pontillo A, Venturini J
PLoS Neglected Tropical Diseases, 19 March 2026
PMID: 41855184 |
PMCID: PMC13001940

This paper is not focused on aspergillosis, but it is relevant to the wider theme of host genetic susceptibility to fungal infection. It adds to the growing literature suggesting that inherited immune variation may partly shape vulnerability to invasive mycoses.

A Case of Disseminated Trichophytosis With Vascular Invasion and Multiple Ulcers: Case Report and Literature Review

Fujino K, Umemoto N, Kakurai M, Yabe H, Maekawa T, Harada K, Makimura K, Shibuya K, Demitsu T
Journal of Dermatology, 19 March 2026
PMID: 41853986

This case is relevant mainly because invasive aspergillosis was initially suspected. It is a useful reminder that other invasive fungal infections may enter the differential diagnosis in immunocompromised patients.

IFUCISTRATEGY: A Spanish Survey on the Management of Invasive Fungal Infection (IFI) in Critically Ill Patients

Zaragoza R, Estella Á, Nuvials X, Robles-Plaza M, Casado-Gómez A
Preprints.org, 17 March 2026
Preprint: PPR1166594

This preprint surveys management practices for invasive fungal infection in critically ill patients. It includes references to pulmonary aspergillosis and reflects continuing emphasis on early testing, bronchoalveolar lavage galactomannan, and timely treatment. As a preprint, it should be interpreted cautiously until peer review is complete.

TET2 germline mutation in a patient with sequential lymphoid malignancies: a novel case report

Mao X, Shen K, Wang J, Wang Z, Ao Q, Wang C, Xiao M
Annals of Hematology, 17 March 2026
PMID: 41843166 |
PMCID: PMC12995931

This paper is included as contextual evidence of aspergillosis occurring in a severely immunocompromised setting. Its relevance is mainly in reinforcing the ongoing burden of pulmonary aspergillosis in haematology patients.

Post-transplant Cyclophosphamide Reduces Bronchiolitis Obliterans Syndrome Risk Through Chronic Graft-versus-Host Disease Prevention: A Multicenter Cohort Study

Eggleston RH, Alkhateeb H, Pennington KM, Zhang Z, Torghabeh MH, Hogan WJ, Khera N, Roy V, Durani U, Yadav H
Chest, 16 March 2026
PMID: 41850483

This paper is not principally about aspergillosis, but may be of indirect relevance to post-transplant lung complications and immunosuppressed populations in whom fungal disease risk remains important.

Overall interpretation

This week’s literature is strongest in three areas: chronic disease ecology, fungal adaptation under azole pressure, and diagnostic complexity. For chronic pulmonary aspergillosis in particular, the most notable message is that disease behaviour may be shaped by more than the fungus alone. The aspergilloma paper supports a richer ecological model involving bacterial adaptation, while the resistance papers suggest that fungal survival under treatment may begin to change before classical resistance becomes obvious.

Together, these studies strengthen the case for thinking about chronic aspergillosis as a dynamic long-term host-microbe-environment problem, rather than a static fungal infection. At the same time, the lung cancer case report is an important reminder that persistent or recurrent disease patterns must still be reviewed critically, especially if the clinical course changes.

What seems most relevant this week?

  • Most important for CPA: the aspergilloma microbiome paper and the two azole adaptation/resistance papers.
  • Most important for ABPA: the ABPA review summarising diagnosis and evolving treatment approaches.
  • Most important for service planning: the surveillance paper arguing for disease-level rather than pathogen-only monitoring.
  • Most important diagnostic caution: lung cancer masquerading as recurrent aspergillosis.

References

by GAtherton

Building fitness with Aspergillosis

Last reviewed: 20 March 2026
Audience: Patients, carers, families, and non-specialists
Applies to: Allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), Aspergillus bronchitis, severe asthma with fungal sensitisation (SAFS)

Why it feels so hard — and how to improve safely

Key points

  • Feeling exhausted after activity is common in aspergillosis and does not mean you are failing.
  • Breathlessness and fatigue are often due to lung changes, not just “lack of fitness”.
  • Pushing too hard can make symptoms worse — pacing is essential.
  • Small, steady increases in activity are more effective than big efforts.
  • Respiratory physiotherapy can make a major difference.
  • Some patients (e.g. with cavities or haemoptysis) need tailored, cautious approaches.

Why exercise feels so difficult

Many people with aspergillosis find that even simple activity can feel exhausting.

This is not just about fitness. It is often due to changes in how the lungs and body work, including:

  • Inflamed or narrowed airways
  • Mucus affecting airflow
  • Reduced oxygen transfer
  • Increased effort needed to breathe

In addition:

  • Long-term illness can reduce muscle strength
  • Treatments such as steroids may affect weight and energy
  • Many people experience post-exertional fatigue (feeling worse after activity)

This means your body is working harder than it used to — even for everyday tasks.

Why “just doing more” can backfire

It is natural to think that pushing harder will improve fitness. However, in aspergillosis this often leads to a cycle:

  • Doing too much on a “good day”
  • Feeling exhausted afterwards
  • Needing longer recovery
  • Losing confidence

This is sometimes called a “boom and bust” cycle.

The goal is not to push harder — it is to build steadily and sustainably.

A safer way to build fitness

1. Find your baseline

Start with what you can do without feeling completely exhausted afterwards.

This may be much less than you expect — and that is normal.

2. Use the 70–80% rule

Only do about 70–80% of what you feel capable of.

This helps prevent setbacks and allows gradual improvement.

3. Break activity into smaller chunks

Short sessions (e.g. 10–15 minutes) with rest in between are often easier than one long effort.

4. Use breathing control

Pursed-lip breathing:

  • Breathe in through your nose
  • Breathe out slowly through pursed lips

This helps keep airways open and reduces breathlessness.

5. Add gentle strength work

Improving muscle strength can reduce breathlessness and improve stamina.

  • Sit-to-stand from a chair
  • Light squats (with support)
  • Step-ups

Start small — 2–3 times per week is enough.

The role of respiratory physiotherapy

Respiratory physiotherapy can be one of the most helpful supports available.

A respiratory physiotherapist can help with:

  • Breathing techniques to reduce breathlessness
  • Airway clearance to manage mucus
  • Tailored exercise plans at the right pace
  • Confidence in what is safe to do

You may be offered this as pulmonary rehabilitation.

If you have not been referred, it is worth asking your GP or specialist team.

⚠️ Important safety advice (including bleeding risk)

Exercise is helpful for many people with aspergillosis — but it is not always appropriate to increase activity without guidance.

Be especially cautious if you have:

  • Coughing up blood (haemoptysis) — current or recent
  • An aspergilloma (fungal ball)
  • Lung cavities
  • A recent flare or worsening symptoms

Why this matters

In some forms of aspergillosis, blood vessels in the lungs can become fragile. Strain or increased pressure in the chest can increase the risk of bleeding.

When to stop and seek advice

  • Coughing up blood (even small amounts)
  • Sudden increase in breathlessness
  • Chest pain or tightness
  • Feeling significantly worse after activity

How to exercise more safely (if stable)

  • Keep activity gentle and controlled
  • Avoid heavy lifting or straining
  • Avoid holding your breath during exertion
  • Build activity gradually

If you are unsure, seek advice from your specialist team or a respiratory physiotherapist before increasing activity.

What progress really looks like

Improvement is rarely a straight line.

  • Some days will be better than others
  • Setbacks are common
  • Progress may be slow but meaningful

This is normal in chronic lung conditions.

When to seek medical advice

Contact your healthcare team if you experience:

  • New or worsening breathlessness
  • Changes in cough or sputum
  • Chest pain
  • Coughing up blood
  • Severe or persistent fatigue

Final message

Living with aspergillosis changes how your body responds to activity.

But improvement is possible — with the right approach.

Build slowly, pace yourself, and get the right support — especially from a respiratory physiotherapist.

In one sentence

Exercise can help — but it must be paced, personalised, and safe for your type of aspergillosis.

Author: Graham Atherton and ChatGPT draft support

For review by: National Aspergillosis Centre

Note: This article is for general information and does not replace medical advice.

by GAtherton

A Drop of Blood, Real-Time Answers

Last reviewed: 20 March 2026
Audience: Patients, carers, families, and non-specialists
Topic: Point-of-care monitoring of antifungal drug levels

New bedside testing for antifungal drugs — and why patients welcome it

For many people taking antifungal medicines, blood tests are an important part of care. These tests help doctors check whether the amount of medicine in the body is too low, too high, or about right.

A new type of technology is being developed to do this much more quickly, using just a single drop of blood placed onto a specialised chip. Instead of sending blood away to a laboratory and waiting days for a result, this kind of test may be able to provide an answer much more quickly, sometimes during the clinic visit itself.

Patients in a recent focus group responded very positively to this idea. They welcomed not only the technology itself, but also what it could mean for their care: less waiting, less uncertainty, fewer trips to hospital, and more personalised treatment.

Key points

  • A new test can measure antifungal drug levels from a drop of blood.
  • The blood is placed on a specialised chip containing tiny sensors.
  • Results may be available much faster than standard laboratory testing.
  • This could help doctors adjust treatment more quickly and more precisely.
  • Patients in a focus group strongly welcomed the technology.
  • Reported benefits included less anxiety, fewer hospital visits, and more confidence in treatment decisions.

What is this new test?

This is a type of point-of-care test. That means it is designed to be used close to the patient, such as in a clinic or at the bedside, rather than sending the sample away to a central laboratory.

In this case, the aim is to measure the level of an antifungal drug in the blood from a very small sample, sometimes just a finger-prick drop. The drop of blood is placed onto a specialised chip. That chip contains tiny channels and sensors that can detect the amount of drug present.

People sometimes describe this type of system as a “lab on a chip” because it performs some of the work of a laboratory in a very small device.

How does the technology work?

The exact science varies between devices, but the general idea is similar.

  1. A small blood sample is taken.
    This may be from a finger prick rather than a larger blood draw.
  2. The blood is placed onto a specialised chip.
    The chip is designed to handle a tiny volume of blood.
  3. The blood moves through microscopic channels.
    These channels guide the sample to the parts of the chip that do the measurement.
  4. Sensors on the chip detect the antifungal drug.
    These sensors are designed to recognise the drug or react to it in a measurable way.
  5. A reader produces a result.
    A connected device reads the signal from the chip and estimates the drug level.

Some systems use electrical signals, some use light, and some use chemical reactions. Patients do not need to understand all the engineering details to understand the main point: the chip is acting like a mini laboratory.

A simple way to think about it is this:

Instead of sending your blood sample to a distant laboratory, this technology brings part of the laboratory to your fingertip.

Why do antifungal drug levels matter?

Some antifungal medicines need careful monitoring because the “right” level can be quite important.

If the drug level is too low, the medicine may not work well enough. If the drug level is too high, side effects may become more likely.

This can be especially relevant for antifungal drugs such as:

  • itraconazole
  • voriconazole
  • posaconazole

Drug levels can vary from person to person for many reasons, including:

  • how well the body absorbs the medicine
  • interactions with other medicines
  • differences in liver function and metabolism
  • changes in health over time

At present, monitoring usually involves sending blood to a laboratory. That works, but it can mean delays. Results may not come back quickly enough to guide decisions during the clinic appointment itself.

A faster bedside test could help clinicians make treatment decisions more quickly and could support more personalised care.

What did patients say about it?

In the patient focus group, this technology was widely welcomed. Patients were not only interested in the novelty of the test. They also recognised several practical benefits that could make day-to-day care easier and safer.

1. Faster results could reduce anxiety

Many patients described the stress of waiting for test results. Waiting can create a sense of uncertainty: Is the treatment working? Is the dose correct? Are side effects more likely?

A test that gives much quicker results was seen as reassuring. Instead of waiting days, patients liked the idea of getting answers much sooner, possibly while still in clinic.

2. Fewer visits could reduce the burden of care

For many people with chronic lung conditions or long-term illness, going to hospital is not a small task. Travel, parking, breathlessness, fatigue, mobility problems, and long waits can make even a short appointment exhausting.

Patients felt that a faster and simpler test could reduce some of this burden, especially if it could be built into a normal appointment or eventually be offered closer to home.

3. More personalised dosing felt important

Patients often understand from experience that medicines do not affect everyone in the same way. One person may tolerate a treatment well, while another may have side effects or absorb the medicine differently.

Because of this, patients valued the idea that treatment could be adjusted based on their own measured drug level, rather than relying only on standard dosing. This gave a stronger sense that care was being tailored to the individual.

4. Closer monitoring gave reassurance about safety

Antifungal drugs can be very helpful, but patients also know that some of them can have side effects and interactions. That can make treatment feel worrying, especially over longer periods.

Patients said that being able to check drug levels more quickly and more easily could help them feel safer. It suggested that treatment was being watched closely rather than left unchecked between appointments.

5. Immediate results could help patients feel more involved

Another important theme was involvement. Patients often feel that blood is taken, results disappear into the system, and decisions come later without much real-time discussion.

By contrast, a bedside result creates the possibility of discussing the number there and then. Patients felt this could help them better understand their treatment and feel more involved in decisions about dose changes and ongoing care.

6. It seemed to fit better with real life

Patients repeatedly emphasised that long-term treatment has to fit around real lives, not just clinic systems. Many welcomed the idea of a test that was quicker, simpler, and potentially more convenient.

In that sense, what patients welcomed was not just a chip or a machine, but a model of care that felt more responsive and more human-centred.

What could this mean for future care?

If this technology proves accurate, reliable, and affordable, it could support a different way of monitoring antifungal treatment.

Possible future benefits could include:

  • drug level testing during the clinic appointment itself
  • faster dose adjustment when levels are too high or too low
  • closer monitoring when starting or changing treatment
  • fewer repeat visits just to check blood levels
  • potential future use in community settings or, one day, at home

It is important to be realistic. New technologies must be carefully tested before they become routine. They need to be shown to be accurate, dependable, and practical in real healthcare settings.

Even so, patients clearly recognised the potential. For them, this is not just about speed. It is about moving toward care that is:

  • more responsive
  • more personalised
  • more convenient
  • less anxiety-provoking

Common questions

Is this available now?

Usually not as a routine test in most healthcare settings. It is still being developed and studied, although interest in this type of monitoring is growing.

Will this replace ordinary blood tests?

Not immediately. Standard laboratory testing is still important. New bedside systems may first be used alongside existing methods while they are being evaluated and introduced.

Would this work for every antifungal drug?

Not necessarily. Some devices may be designed for specific drugs first. Wider use would depend on the technology and the evidence supporting it.

Could this be used at home?

Possibly one day, but that is likely to depend on how reliable, affordable, and easy to use the technology becomes. For now, clinic or bedside use is the more immediate possibility.

Why is a drop-of-blood test appealing to patients?

Because it may mean quicker answers, less uncertainty, fewer hospital trips, and more confidence that treatment decisions are based on what is happening in their own body.

When to seek medical advice

You should contact your healthcare team if you:

  • develop new or worsening side effects from your antifungal medicine
  • feel your treatment is not helping
  • have concerns about drug interactions with other medicines
  • are unsure whether to continue, stop, or change your medication

A new bedside test could support treatment decisions, but it would not replace medical advice. Symptoms, scans, blood tests, and clinical review would still matter.

Final thoughts

This new chip-based bedside technology may sound futuristic, but the reason patients welcomed it is very straightforward.

They saw the possibility of care that is faster, clearer, safer, and better adapted to real life.

In other words, this is about more than measuring a drug level from a drop of blood. It is about moving away from delayed, one-size-fits-all monitoring and toward real-time, personalised, patient-centred care.

In one sentence

A tiny chip and a drop of blood could help doctors adjust antifungal treatment more quickly — and patients believe that could make care less stressful, less burdensome, and more personal.

Author: Graham Atherton and ChatGPT draft support

For review by: National Aspergillosis Centre / relevant clinical or research reviewer

Note: This article is for general information and should not be used as a substitute for medical advice.

by GAtherton

Understanding the Journey to Diagnosis (Start Here)

Last reviewed: 18 March 2026

Who this page is for: Patients, carers, and clinicians who want to understand why diagnosis can sometimes take time in aspergillosis and other chronic or complex conditions.
For many people, diagnosis is not a single moment. It is a journey.Symptoms may begin gradually, overlap with more common conditions, respond only partly to treatment, or take time to form a recognisable pattern. This can be confusing, frustrating, and sometimes frightening.This short series explores why that happens, what uncertainty can feel like, and why people are often not alone in having a long path to diagnosis.The series is written for patients and carers first, but we hope it will also help clinicians, families, and others understand the reality of the diagnostic journey more clearly.

Key points

  • Aspergillosis can be difficult to diagnose because symptoms often overlap with more common illnesses.
  • Long diagnostic journeys are common in many chronic and uncommon conditions, not just aspergillosis.
  • Uncertainty does not mean symptoms are unreal.
  • Diagnosis often becomes clearer over time, as symptoms, scans, tests, and patterns build up.
  • Good communication, ongoing review, and specialist input can make a major difference.
Different people may take different routes, but many share the same uncertainty before diagnosis becomes clear.

Why we created this series

People living with aspergillosis often tell us that the hardest part was not only the illness itself, but the time before they had an answer. Many describe repeated symptoms, multiple appointments, courses of treatment that only partly helped, and a growing sense that something still did not fit.

This experience is common in conditions such as chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA), but it is also seen much more widely across medicine.

We created this series to help make sense of that process in a way that is:

  • clear and accessible for patients and carers
  • respectful of clinicians working within complex systems
  • honest about uncertainty, delay, and emotional impact
  • useful for improving understanding on both sides

The articles in this series

1. Why Aspergillosis Is So Hard to Diagnose

This article explains why aspergillosis can be difficult to recognise, why medicine usually starts with more common explanations, and how diagnosis often depends on patterns building up over time rather than one single test.

Best for: understanding the overall process and why delays can happen.

2. When Symptoms Are Real but Answers Are Not: Understanding Uncertainty

This article looks at the emotional and communication side of the diagnostic journey, including why patients may feel unheard, what clinicians may mean when they speak cautiously, and why unexplained symptoms are still real symptoms.

Best for: understanding uncertainty, communication gaps, and the experience of not yet having answers.

3. Why Diagnosis Can Take Time — and Why You Are Not Alone

This article places the diagnostic journey in a wider context, showing that long paths to diagnosis are common in many chronic and complex conditions, and offering reassurance that patients are not alone in this experience.

Best for: reassurance, perspective, and recognising that this journey is shared by many others.

Who may find this series helpful

This series may be useful if you are:

  • a patient with ongoing respiratory symptoms and no clear diagnosis yet
  • a carer or family member trying to understand what your loved one is going through
  • a person recently diagnosed with aspergillosis and looking back on a long journey
  • a general practitioner, respiratory clinician, nurse, or allied health professional wanting to better understand the patient perspective

It may also help people with other chronic conditions, because many of the same themes—uncertainty, overlap of symptoms, repeated reassessment, and eventual recognition—are seen across a wide range of illnesses.

When to seek medical advice

Seek medical advice if you have ongoing or worsening symptoms that are not improving as expected, especially if they keep returning or no longer fit the original explanation.

Seek urgent medical advice if you have symptoms such as:

  • coughing up blood
  • rapidly worsening breathlessness
  • new chest pain
  • significant unexplained weight loss
  • high fever or signs of severe infection

If you already have an underlying lung condition and your usual treatment no longer seems to be working, it is reasonable to ask whether the diagnosis needs to be reviewed.

A final thought: a long path to diagnosis can feel isolating, but it is a recognised part of many chronic illnesses. Better understanding can help patients feel less alone and help clinicians recognise these journeys more clearly.

by GAtherton

Why Diagnosis Can Take Time — and Why You Are Not Alone

Last reviewed: 18 March 2026

Who this page is for: Patients and carers who have been living with symptoms for some time without a clear diagnosis, including those eventually diagnosed with aspergillosis.

Key points

  • Long diagnostic journeys are common in many chronic and rare conditions—not just aspergillosis.
  • Delays do not mean your symptoms were not real or important.
  • Diagnosis often becomes clear over time, as patterns develop.
  • Many patients go through similar experiences before reaching answers.
  • Specialist centres play an important role when conditions are complex.

You are not alone in this

One of the most important things to understand is this:

Long and difficult diagnostic journeys are common—especially in chronic or complex illness.

Many people living with conditions such as chronic pulmonary aspergillosis (CPA) or allergic bronchopulmonary aspergillosis (ABPA) describe months or years of symptoms before a clear diagnosis was made.

This experience, while frustrating, is not unusual—and it does not mean your care has failed.

This happens in many conditions

Aspergillosis is not unique in this respect.

Similar diagnostic journeys are seen in:

  • chronic lung diseases
  • autoimmune conditions
  • rare infections
  • conditions with overlapping symptoms (e.g. fatigue syndromes)

In all of these, the same pattern often occurs:

  • early symptoms are non-specific
  • common conditions are treated first
  • tests may initially be normal
  • the true pattern only becomes clear over time

Why time helps diagnosis

Many conditions only become recognisable as patterns develop over time.

Although it can feel like delay, time often provides essential information.

Patterns emerge

  • symptoms become more consistent
  • flare-ups follow recognisable triggers
  • response to treatment becomes clearer

Tests become more informative

  • changes appear on imaging (e.g. CT scans)
  • blood markers become more clearly abnormal
  • microbiology results become more consistent

What was unclear early on can become much more visible later.

The turning point

Many patients describe a moment when things begin to change:

  • symptoms no longer fit common conditions
  • treatments stop working as expected
  • a clinician recognises a pattern

This is often the point where less common diagnoses—including aspergillosis—are considered.

The role of specialist centres

Complex conditions are often best diagnosed in specialist centres with experience in that field.

In the UK, the National Aspergillosis Centre provides:

  • expert multidisciplinary assessment
  • access to specialist diagnostics
  • experience in recognising patterns of disease

Referral to a specialist centre is often a key step in reaching a diagnosis.

The emotional impact

Long periods without answers can be deeply challenging.

Patients often describe:

  • frustration and uncertainty
  • feeling unheard or misunderstood
  • loss of confidence in their own body

These reactions are entirely understandable.

Your experience is valid—even if the diagnosis took time to emerge.

Moving forward

Once a diagnosis is made, many patients feel a sense of relief—even if treatment is still needed.

A diagnosis provides:

  • an explanation for symptoms
  • a direction for treatment
  • a clearer future plan

Even before diagnosis, it is important to remember:

You are still on a pathway—just not always a straight one.

Common questions

Does a long delay mean something was missed?

Not necessarily. Many conditions are only diagnosable once they have developed further.

Should I have been referred earlier?

Sometimes earlier referral is helpful, but it usually depends on how symptoms evolve over time.

Is this unique to aspergillosis?

No—this pattern is seen across many chronic and rare conditions.

Related pages

by GAtherton

Why Aspergillosis Is So Hard to Diagnose


Last reviewed: 18 March 2026
Who this page is for: Patients, carers, general practitioners, respiratory clinicians, specialist nurses, and anyone trying to understand why the road to diagnosis can be long and confusing.

Key points

  • Aspergillosis is often difficult to diagnose because its symptoms can look very similar to those of more common conditions.
  • Diagnosis usually depends on several pieces of evidence being brought together, rather than one simple test.
  • Doctors are trained to consider common conditions first, because this is usually the safest and most efficient approach.
  • This approach works well for many patients, but it can delay recognition of conditions such as aspergillosis.
  • Delays are often caused by the way healthcare systems are organised, not by lack of care or effort from individual clinicians.
  • Patients can help by keeping a clear record of symptoms, tests, treatments, and how things have changed over time.
Many people with aspergillosis say that one of the hardest parts of their illness was not just the symptoms, but the long and uncertain path to getting an answer. Some were treated several times for asthma flare-ups, chest infections, or chronic obstructive pulmonary disease (COPD) before fungal disease was seriously considered.This can be frightening and frustrating. It is natural to ask: Why did it take so long?The answer is usually not that nobody was trying. More often, it is because aspergillosis does not fit neatly into the way modern medicine is designed to recognise disease.

Why diagnosis can be difficult

Aspergillosis is not a single illness but a group of conditions caused by Aspergillus, a mould commonly found in the environment. These include:

Diagnosis usually depends on combining:

  • symptoms over time
  • CT scan findings
  • blood tests (including immunological tests)
  • sputum microbiology
  • clinical history

There is rarely a single “yes or no” test, which is why diagnosis can take time.

What the patient journey often looks like

Early symptoms

Symptoms such as cough, breathlessness, fatigue, or sputum are common across many conditions including bronchiectasis, asthma, and infection.

Treatment for common conditions

Initial treatment often includes antibiotics, inhalers, or steroids. These are appropriate first steps based on clinical guidelines such as those from the British Thoracic Society (BTS).

Ongoing symptoms

When symptoms persist or return, further investigation is usually needed.

The turning point

At some stage, fungal disease may be considered and tests for Aspergillus are performed.

Why doctors tackle common conditions first

Why do doctors start with common conditions?

Doctors treat common diseases first, prioritizing efficiency, patient safety, and high-probability outcomes. This approach, considering the most likely diagnosis first, helps manage patient health efficiently and effecctively before investigating rare or complex conditions.

This approach is safe and effective for most people, but conditions like aspergillosis can sit outside these usual pathways.

Where delays can happen

Overlap of symptoms

Symptoms overlap with many conditions, including tuberculosis and lung cancer.

No single definitive test

Diagnosis often requires combining multiple test results rather than relying on one.

Gradual disease progression

Conditions such as CPA may evolve over months or years.

Multiple conditions

Patients may have more than one lung condition at the same time.

Why this is often about the system, not the individual doctor

Healthcare systems are designed to manage large numbers of patients efficiently and safely. This means prioritising common conditions first.

However, aspergillosis often requires specialist input. In the UK, this may include referral to the National Aspergillosis Centre, which provides expert assessment and management.

International guidance from organisations such as ESCMID (European Society of Clinical Microbiology and Infectious Diseases) also highlights the complexity of fungal diseases.

What patients can do

  • Keep a record of symptoms and treatments
  • Ask when diagnosis should be reviewed
  • Discuss whether further tests are needed
  • Use trusted information sources such as our diagnosis guide

A more balanced way to think about delay

Diagnosis is often not a single event but a process that unfolds over time.

The goal is to recognise patterns earlier and ensure patients who need specialist input are identified sooner.

Common questions

Why was I treated for other conditions first?

Because those conditions are more common and more likely.

Should I ask about aspergillosis?

Yes, especially if symptoms are persistent or unusual—but it should be part of a broader discussion.

When to seek medical advice

  • Persistent or worsening symptoms
  • Coughing up blood
  • Unexplained weight loss

References and further reading

by GAtherton